Brian Costello
Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Brian Costello as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:05 UTC. Open this list on ClinicalTrials.gov
- N/ANCT02944357 · Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing SurgeryMayo Clinic · withdrawn · Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma · principal investigator
- Ph2NCT01767636 · Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney CancerMayo Clinic · completed · Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma · principal investigator
- Ph1NCT00949949 · Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard TherapyMayo Clinic · completed · Cholangiocarcinoma of the Gallbladder, Localized Gallbladder Cancer, Unresectable Gallbladder Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS26120110009 · NCI · MAYO CLINIC ROCHESTER · fiscal years 2015 to 2016 · $248,397 awarded in 2016Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2011 to 2026Named on NCT02944357, NCT00949949
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:05 UTC. The ranking covers the 200 most relevant of 22 PubMed records, and a shared surname and initials can bring in a namesake. All 22 on PubMed
- Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study.J Am Coll Cardiol · 2017535 citationsRCR 22.5
- Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).J Clin Oncol · 2018380 citationsRCR 13.7
- Alcohol Abstinence in Drinkers with Atrial Fibrillation.N Engl J Med · 2020340 citationsRCR 18.6
- Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.Blood · 2018130 citationsRCR 4.1
- Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial.JACC Cardiovasc Imaging · 2023119 citationsRCR 12.9
- Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The BREXIT Study.Circulation · 2023115 citationsRCR 13.9
- 87 citationsRCR 2.8
- Regression of Diffuse Ventricular Fibrosis Following Restoration of Sinus Rhythm With Catheter Ablation in Patients With Atrial Fibrillation and Systolic Dysfunction: A Substudy of the CAMERA MRI Trial.JACC Clin Electrophysiol · 201864 citationsRCR 2.4
- Preemptive rofecoxib and dexamethasone for prevention of pain and trismus following third molar surgery *.Oral Surg Oral Med Oral Pathol Oral Radiol Endod · 200552 citationsRCR 2.5
- Catheter Ablation Versus Medication in Atrial Fibrillation and Systolic Dysfunction: Late Outcomes of CAMERA-MRI Study.JACC Clin Electrophysiol · 202046 citationsRCR 2.6